Nephrology · Clinical Calculator · Hemodialysis

HDx & Convection Toolkit Albumin · Budget · β2M · HDF Volume

Four implementation tools for membrane and modality decisions: follow serum albumin after a dialyzer switch, model the budget impact and break-even price of expanded hemodialysis (HDx), compute a β2-microglobulin reduction ratio with optional volume correction, and audit post-dilution hemodiafiltration convection volume against the CONVINCE benchmark.

Published: References: 4 Read time:

← All calculators & tools  ·  Related guide →

Instructions
  1. Albumin trend: enter the switch date, then each predialysis albumin with its date, unit, assay and any flag. Rows before the switch form the baseline (median); rows after it are compared against that baseline.
  2. Budget & break-even: enter annual eligible sessions, the share you expect to switch, dialyzer prices in pesos, and any other incremental costs or reimbursement. All inputs are your own local quotes.
  3. β2M reduction ratio: enter paired pre- and post-session β2-microglobulin from the same assay; add pre/post weights to apply the extracellular-volume correction.
  4. HDF convection: choose the dilution mode and enter substitution plus net ultrafiltration, or a machine-reported total.

All computation runs in your browser; no values are stored or transmitted. Use synthetic or de-identified values when teaching.

When to Use

Use these tools when a unit is running or planning a selective expanded hemodialysis (HDx) pilot with medium cut-off (MCO) dialyzers, comparing it with high-volume online hemodiafiltration (HDF), or auditing delivered convection. They support the workflow in Expanded Hemodialysis (HDx).

⚠️

What these tools do not do

None of them predicts survival, hospitalization or symptom benefit, or chooses a membrane. No validated HDx benefit score exists. Serum albumin and catalog sieving coefficients cannot estimate dialysate albumin loss; that needs measured effluent. Never import hospitalization savings from observational studies into the budget model.

Albumin Trend After a Dialyzer Switch

Follows the change in predialysis serum albumin concentration relative to a pre-switch baseline. Pooled trials show an average dip of about 0.1 g/dL in the first 24 weeks with MCO membranes, recovering thereafter; larger or persistent falls warrant a search for other causes.

First session on the new dialyzer.
Rows with a different assay are excluded from change calculations.
DateAlbuminUnitPhaseAssayFlag

⚕ Baseline = median of comparable pre-switch values. Change = current − baseline; percent change = 100 × (current − baseline) ÷ baseline. Values in g/L are divided by 10. Albumin concentration reflects synthesis, inflammation, dilution, intake and losses — this tool estimates concentration change only; interpretation belongs to the clinician and the unit's review pathway.

HDx Budget Impact and Break-even Price

Clinic perspective, one currency per scenario (Philippine peso by default). Separates clinic cost from payer reimbursement and patient charges. Enter only locally sourced, dated quotes.

Share of eligible sessions switched to HDx.
Extra monitoring, labs, supplies. Enter a negative value for a saving.
Training, protocol development, stock.
Only a documented extra payment per HDx session.
Optional.

⚕ N = sessions × adoption. Gross annual cost = N × (HDx price − comparator price + other variable cost) + fixed cost. Net clinic impact = gross − N × incremental reimbursement. Break-even HDx price = comparator price − other variable cost + incremental reimbursement − fixed cost ÷ N (N > 0). Negative impact = modeled saving. Hospitalization or survival effects are deliberately excluded.

β2-Microglobulin Reduction Ratio

Session reduction ratio for paired pre- and post-dialysis β2-microglobulin (β2M) from the same assay and session, with optional correction of the post-dialysis value for extracellular-volume contraction (Bergström formula, extracellular volume ≈ 20% of post-dialysis weight).

Same assay and units as the pre value.

⚕ RR% = 100 × (1 − Cpost ÷ Cpre). Corrected Cpost = Cpost ÷ [1 + (Wpre − Wpost) ÷ (0.2 × Wpost)]. A reduction ratio is a concentration change over one session; it is not clearance, mass removed or an adequacy target, and it ignores post-dialysis rebound.

HDF Delivered Convection Audit

Total convection volume for a post-dilution online HDF session, compared with the ≥ 23 L/session eligibility threshold and 25.3 L mean delivered volume in the CONVINCE trial.

⚕ Total convection = delivered substitution + net ultrafiltration (same session, same machine definitions). The CONVINCE benchmark applies to post-dilution HDF in its studied population; pre- and mixed-dilution volumes are not comparable. Volume says nothing about HDx, access adequacy or filtration fraction — see the TMP & filtration fraction calculator.

Formulae & Evidence

Formulae

QuantityEquation
Albumin changeΔ = current − median(pre-switch); %Δ = 100 × Δ ÷ baseline
Switched sessionsN = eligible sessions × adoption fraction
Gross annual costN × (PHDx − Pcomp + Cvar) + Cfixed
Break-even HDx pricePcomp − Cvar + R − Cfixed ÷ N
β2M reduction ratio100 × (1 − Cpost ÷ Cpre)
Volume-corrected CpostCpost ÷ [1 + ΔW ÷ (0.2 × Wpost)]
HDF convectionSubstitution volume + net UF (post-dilution)

Key numbers

  • MCO vs high-flux: dialysate albumin +2.31 g/session; predialysis albumin −0.12 g/dL in the first 24 weeks, −0.02 g/dL thereafter (Kandi et al., 2022).
  • CONVINCE: participants able to reach ≥ 23 L/session; mean delivered 25.3 L; all-cause death HR 0.77 (Blankestijn et al., 2023).
  • FRENCHIE post hoc analysis: post-dilution HDF median 23.2 L/session; β2M reduction ratio 69.6% vs 58.7% with high-flux HD, using Bergström-corrected post values (Canaud et al., 2025).
Important: These calculators are educational aids for unit-level review. They do not predict clinical outcomes or select a membrane or modality. Use local device registration, instructions for use, contracted prices and unit protocols.
References 4 sources
  1. Kandi, M., Brignardello-Petersen, R., Couban, R., Wu, C., & Nesrallah, G. (2022). Effects of medium cut-off versus high-flux hemodialysis membranes on biomarkers: A systematic review and meta-analysis. Canadian Journal of Kidney Health and Disease, 9, 20543581211067090. https://doi.org/10.1177/20543581211067090
  2. Blankestijn, P. J., Vernooij, R. W. M., Hockham, C., Strippoli, G. F. M., Canaud, B., Hegbrant, J., Barth, C., Covic, A., Cromm, K., Cucui, A., Davenport, A., Rose, M., Török, M., Woodward, M., Bots, M. L., & CONVINCE Scientific Committee Investigators. (2023). Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. The New England Journal of Medicine, 389(8), 700–709. https://doi.org/10.1056/NEJMoa2304820
  3. Canaud, B., Davenport, A., Morena-Carrere, M., Amico, M., Molinari, N., & Cristol, J. P. (2025). Continuous beta-2 microglobulin-based clearance highlights superiority of high-dose HDF over high-flux HD in predicting outcomes. Scientific Reports, 15(1), 20421. https://doi.org/10.1038/s41598-025-07497-2
  4. Ikizler, T. A., Burrowes, J. D., Byham-Gray, L. D., Campbell, K. L., Carrero, J. J., Chan, W., Fouque, D., Friedman, A. N., Ghaddar, S., Goldstein-Fuchs, D. J., Kaysen, G. A., Kopple, J. D., Teta, D., Yee-Moon Wang, A., & Cuppari, L. (2020). KDOQI clinical practice guideline for nutrition in CKD: 2020 update. American Journal of Kidney Diseases, 76(3 Suppl 1), S1–S107. https://doi.org/10.1053/j.ajkd.2020.05.006
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides